Latest News

MSCA 2017 Presidency conference ‘Mobility takes research further’

13 March 2017

Read more ...

aDDRess and CodeAge Final ITN Conference: Abstract book now online!

03 November 2016

Read more ...

Björn Schumacher presentation on BR alpha Campus

7 October 2016

Read more ...

Gallery

gallery prev2

(Click image to open the gallery)

Contact

Let us hear from you.
This email address is being protected from spambots. You need JavaScript enabled to view it. or complete our contact form.

Thanks to

sponsors1sponsors2sponsors3


Prof. Dr. K. Lenhard Rudolph
Leibniz-Institute for Age Research - Fritz Lipmann Institute e.V. (FLI), Germany

Image

Leibniz-Institute for Age Research - Fritz Lipmann Institute e.V. (FLI)

Beutenbergstrasse 11

07745 Jena, Germany
KLRudolph@fli-leibniz.de
Tel: +49 3641 656350
www.fli-leibniz.de

Image

Karl Lenhard Rudolph is Director of the Leibniz-Institute for Age Research – Fritz Lipmann Institute e.V. (FLI), Jena, Germany. After his studies in medicine and biology at Georg August University Göttingen, Karl Lenhard Rudolph spent a postdoctoral period at the Albert Einstein College in New York and the Dana Faber Cancer Institute in Boston. In 2001, he obtained an Emmy Noether fellowship to establish his own research group at Hannover Medical School. In 2006, he received a Heisenberg professorship. In 2009, he was awarded the Gottfried Wilhelm Leibniz Prize for his groundbreaking work on Telomeres

Research Interests:

The Rudolph laboratory investigates the role of telomere dysfunction in stem cell ageing in mammalian disease models. Telomere shortening limits the proliferative capacity of human fibroblast to 50-75 cell divisions by inducing senescence or apoptosis. There is growing evidence that telomere shortening impacts on human ageing, diseases, and cancer: (i) Telomere shortening occurs in almost all human tissues during human ageing; (ii) Telomere shortening is accelerated in chronic human disease; (iii) Telomere shortening and telomerase reactivation occur in the vast majority of human cancers; (iv) Telomerase mutations are associated with a shortened lifespan, organ failure, and increased cancer risk in humans